• Explore /
  • Poster
  • / First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.

First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.

Abstract Video & Slides Poster

Authors

null

Shubham Pant

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

Shubham Pant , Muhammad Furqan , Raghad Muhsin Abdul-Karim , Vincent Chung , Craig E. Devoe , Melissa Lynne Johnson , Alexis Diane Leal , Haeseong Park , Zev A. Wainberg , Esther Welkowsky , Christopher M. Haqq , Eileen Mary O'Reilly , Colin D. Weekes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Vaccines

Clinical Trial Registration Number

NCT04853017

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS2701)

DOI

10.1200/JCO.2022.40.16_suppl.TPS2701

Abstract #

TPS2701

Poster Bd #

338a

Abstract Disclosures

Similar Posters

First Author: Zev A. Wainberg

First Author: Maria Pia Morelli

First Author: Toshihiko Doi

First Author: Craig E. Devoe